XML 75 R66.htm IDEA: XBRL DOCUMENT v3.25.3
Surface Acquisition - Additional Information (Details)
 3 Months Ended 12 Months Ended
Sep. 08, 2023
USD ($)
item
$ / shares
shares
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Organization and Significant Accounting Policies        
Goodwill       $ 943,000
Net impairment charge     $ 6,772,000  
Impairment charge     $ 0 0
Contingent consideration, current       3,300,000
Novartis Institutes        
Organization and Significant Accounting Policies        
Impairment charge   $ 10,600,000    
Surface Acquisition        
Organization and Significant Accounting Policies        
Business Combination, Number of Shares Issued in Exchange of Each Share of Acquiree | shares 0.196      
Share price | $ / shares $ 5.2831      
Contingent value right per share | item 1      
Contingent value rights payment period 10 years      
Business combination consideration transferred $ 64,596,000      
Business Combination, Number of Shares Issued to Former Employees of Acquiree shares | shares 161,100      
Goodwill $ 0      
Business Combination, Number of Out Licensed Partnership Program | item 2      
Fair value of the contingent consideration   3,800,000    
Contingent consideration, current   0    
Acquisition related costs       $ 5,100,000
Surface Acquisition | Novartis Institutes        
Organization and Significant Accounting Policies        
Net impairment charge   $ 6,800,000    
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, General and Administrative Expense    
Impairment charge   $ 10,600,000    
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, General and Administrative Expense    
Surface Acquisition | Surface GSK Agreement        
Organization and Significant Accounting Policies        
Milestone and royalty based CVR payments (as percent) 70.00%      
Surface Acquisition | Surface's SRF114 proprietary drug product candidate        
Organization and Significant Accounting Policies        
Upfront payment based CVR payments (as percent) 25.00%      
Surface Acquisition | Surface's SRF388 proprietary drug product candidate        
Organization and Significant Accounting Policies        
Upfront payment based CVR payments (as percent) 50.00%